Dr. Roffler, Steve R. 's publons link picture

Dr. Roffler, Steve R.

Distinguished Research Fellow
Division Chief
  • 02-2652-3079 (Lab) (Room No: N233)
  • 02-2782-9142 (Fax)

  1. Antibody Engineering
  2. Directed Molecular Evolution
  3. Prodrugs

Education and Positions:
  • Ph.D. University of California, Berkeley

1. Antibody engineering: We are engineering and investigating bispecific antibodies to deliver nanomedicines into cancer cells for improved anticancer selectivity and efficacy.    

2. Nanomedicine: New approaches to stably load and retain hydrophobic drugs in liposomal nanocarriers are under development.    

3. Directed molecular evolution: We perform directed molecular evolution of human enzymes for antibody-directed enzyme prodrug therapy. 

 4. Prodrug therapy: Anticancer prodrugs that are selectively activated in the tumor microenvironment are under investigation to improve the selectivity and therapeutic efficacy of cancer treatment. 

5. Anti-PEG antibodies: We develop antibodies to assay PEGylated drugs in human serum and are extending these studies to investigating the impact of pre-existing and induced anti-PEG antibodies on the therapeutic efficacy and safety of PEGylated medicines.

Our Team
Team photo

Journal 170 Book 2

  1. Lin YC, Chen BM, Tran TTM, Chang TC, Al-Qaisi TS, Roffler SR* Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. Journal of controlled release : official journal of the Controlled Release Society 354, 354-367 (2023-01) [JCR] [WOS]
  2. Bavli Y, Chen BM, Gross G, Hershko A, Turjeman K, (Roffler S*), Barenholz Y* Anti-PEG antibodies before and after a first dose of Comirnaty(R) (mRNA-LNP-based SARS-CoV-2 vaccine). Journal of controlled release : official journal of the Controlled Release Society 354, 316-322 (2023) [JCR] [WOS]
  3. Burnouf PA, (Roffler SR), Wu CC, Su YC Glucuronides: From biological waste to bio-nanomedical applications. Journal of controlled release : official journal of the Controlled Release Society 349, 765-782 (2022-09) [JCR] [WOS]
  4. Sahoo BK, Lin YC, Tu CF, Lin CC, Liao WJ, Li FA, Li LH, Mou KY, (Roffler SR), Wang SP, Yeh CT, Yao CY, Hou HA, Chou WC, Tien HF, Yang RB* Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia. Haematologica 10.3324/haematol.2022.281151, x (2022-08) [JCR] [WOS]
  5. Nguyen MT, Shih YC, Lin MH, (Roffler SR), Hsiao CY, Cheng TL, Lin WW, Lin EC, Jong YJ, Chang CY, Su YC Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Communications chemistry 5(1), 88 (2022-08) [JCR] [WOS]
  6. Lin HJ, Liang TL, Chang YY, Liu DZ, Fan JY, (Roffler SR), Lin SY Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics 14(6), 10.3390/pharmaceutic (2022-07) [JCR] [WOS]
  7. Kim J, Li C, Wang H, Kaviraj S, Singh S, Savergave L, Raghuwanshi A, Gil S, Germond A, Baldessari A, Chen B, (Roffler S), Fender P, Drescher C, Carter D, Lieber A Translational development of a tumor junction opening technology. Scientific reports 12(1), 7753 (2022-05) [JCR] [WOS]
  8. Cheng WJ, Chuang KH, Lo YJ, Chen M, Chen YJ, (Roffler SR), Ho HO, Lin SY, Sheu MT Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy. Journal of controlled release : official journal of the Controlled Release Society 344, 235-248 (2022-04) [JCR] [WOS]
  9. Wang H, Li C, Obadan AO, Frizzell H, Hsiang TY, Gil S, Germond A, Fountain C, Baldessari A, Roffler S, Kiem HP, Fuller DH, Lieber A In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor. Human gene therapy 33(7-8), 389-403 (2022-04) [JCR] [WOS]
  10. Cheng KW, Tseng CH, Chen IJ, Huang BC, Liu HJ, Ho KW, Lin WW, Chuang CH, Huang MY, Leu YL, (Roffler SR), Wang JY, Chen YL, Cheng TL Inhibition of gut microbial beta-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. Pharmacological research 177, 106115 (2022-03) [JCR] [WOS]

Tseng, Yi-Han
Chang, Shelly
Chiu, Po-Chuan
Burnouf, Pierre-Alain
Burnouf, Pierre-Alain
Wu, Penny
Tang, Hsiyang
Lin, Sam
Chang, Deng-Yuan(Peter)
Yang, Seymour
Yang, Seymour
Lin, Ronald
Lin, Ronald
Prijovich, Sunny